Health Care Costs Associated With Incident Complications in Patients With Type 2 Diabetes in Germany
The DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim of this study is to provide reliable regression-based estimates of costs associated with different type 2 diabetes complications. RESEARCH DESIGN AND METHODS: We used nationwide statutory health insurance (SHI) data from 316,220 patients with type 2 diabetes. Costs for inpatient and outpatient care, pharmaceuticals, rehabilitation, and nonmedical aids and appliances were assessed in the years 2013–2015. Quarterly observations are available for each year. We estimated costs (in 2015 euro) for complications using a generalized estimating equations model with a normal distribution adjusted for age, sex, occurrence of different complications, and history of complications at baseline, 2012. Two- and threefold interactions were included in an extended model. RESULTS: The base case model estimated total costs in the quarter of event for the example of a 60- to 69-year-old man as follows: diabetic foot €1,293, amputation €14,284, retinopathy €671, blindness €2,933, nephropathy €3,353, end-stage renal disease (ESRD) €22,691, nonfatal stroke €9,769, fatal stroke €11,176, nonfatal myocardial infarction (MI)/cardiac arrest (CA) €8,035, fatal MI/CA €8,700, nonfatal ischemic heart disease (IHD) €6,548, fatal IHD €20,942, chronic heart failure €3,912, and angina pectoris €2,695. In the subsequent quarters, costs ranged from €681 for retinopathy to €6,130 for ESRD. CONCLUSIONS: Type 2 diabetes complications have a significant impact on total health care costs in the SHI system, not only in the quarter of event but also in subsequent years. Men and women from different age-groups differ in their costs for complications. Our comprehensive estimates may support the parametrization of diabetes models and help clinicians and policy makers to quantify the economic burden of diabetes complications in the context of new prevention and treatment programs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nine articles [50–58] considered costs associated with DR and its associated complications (i.e. DMO).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [51]
In the citing paper
“Costs pertaining to DR and its complications (including DMO) were combined in three studies [50, 51, 53], whereas costs in patients affected by both DR and DMO simultaneously were reported in two studies [52, 53] (Supplementary Tables 3 and 8).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [51]
In the citing paper
“Of note, eight studies [47–53, 59] did not distinguish between costs of different conditions, further hindering the interpretation.”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [51]
Citations
Cites
Vos, T., Allen, C., Arora, M., Barber, R. M., Bhutta, Z. A., Brown, A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31678-6 · Cited by 7,253
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives
Chen, L., Magliano, D. J., & Zimmet, P. Z. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.183 · Cited by 2,227 · cited 1×
“The shift in risk factors aswell as demographics is contributing to the increasing prevalence worldwide, especially among younger age-groups (3).”
BackgroundThe Economic Costs of Type 2 Diabetes: A Global Systematic Review
Seuring, T., Archangelidi, O., & Suhrcke, M. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0268-9 · Cited by 837 · cited 1×
“which is further driven by the occurrence ofmultiple heterogeneous complications (4).”
BackgroundReview of statistical methods for analysing healthcare resources and costs
Mihaylova, B., Briggs, A., O'Hagan, A., & Thompson, S. G. (2011) · Health Economics · doi:10.1002/hec.1653 · Cited by 767 · cited 1×
“In line with literature recommendations, we can assume a near normality of the sample means, as the sample size is sufficiently large and the proportion of zero costs relatively small (,2%) (30).”
BackgroundClarke, P. M., Gray, A. M., Briggs, A., Farmer, A. J., Fenn, P., Stevens, R. J., Matthews, D. R., Stratton, I. M., Holman, R. R., & on behalf of the UK Prospective Diabetes Study (UKPDS) Group (2004) · Diabetologia · doi:10.1007/s00125-004-1527-z · Cited by 615
Sex and gender differences in health: Science & Society Series on Sex and Science
Regitz‐Zagrosek, V. (2012) · The EMBO Reports · doi:10.1038/embor.2012.87 · Cited by 572
The CDC Diabetes Cost-effectiveness Group (2002) · JAMA · doi:10.1001/jama.287.19.2542 · Cited by 508
Revealing the cost of Type II diabetes in Europe
Jönsson, B. (2002) · Diabetologia · doi:10.1007/s00125-002-0858-x · Cited by 392
Kassenärztliche Bundesvereinigung
(1985) · Oncology Research and Treatment · doi:10.1159/000215622 · Cited by 306
Research works printed but not linked: 3
- Tamayo, 2016, The prevalence and incidence of diabetes in Germany, Dtsch Arztebl Int, 113, 177
- Chang, 2012, Validating the adapted Diabetes Complications Severity Index in claims data, Am J Manag Care, 18, 721
- Robert Koch Institute, 2014, Diabetes Mellitus: Fact Sheet for GEDA 2012: Results of the “Health in Germany Study 2012.”
Cited by
Williams, R., Karuranga, S., Malanda, B., Saeedi, P., Basit, A., Besançon, S., Bommer, C., Esteghamati, A., Ogurtsova, K., Zhang, P., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108072 · Cited by 861
Socioeconomic inequalities and type 2 diabetes complications: A systematic review
Tatulashvili, S., Fagherazzi, G., Dow, C., Cohen, R., Fosse, S., & Bihan, H. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.11.001 · Cited by 196
The cost of diabetes care-an elephant in the room
Riddle, M. C., & Herman, W. H. (2018) · Diabetes Care · doi:10.2337/dci18-0012 · Cited by 191
Schernthaner, G., Shehadeh, N., Ametov, A. S., Bazarova, A. V., Ebrahimi, F., Fasching, P., Janež, A., Kempler, P., Konrāde, I., Lalić, N. M., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01154-w · Cited by 164
Wan, H., Wang, Y., Fang, S., Chen, Y., Zhang, W., Xia, F., Wang, N., & Lu, Y. (2020) · Journal of Diabetes Research · doi:10.1155/2020/6219545 · Cited by 156
Andersson, E., Persson, S., Hallén, N., Ericsson, Å., Thielke, D., Lindgren, P., Carlsson, K. S., & JENDLE, J. H. (2020) · Diabetologia · doi:10.1007/s00125-020-05277-3 · Cited by 125
Bioactive Compounds and Pharmacological Potential of Pomegranate (Punica granatum) Seeds - A Review
Fourati, M., Smaoui, S., Hlima, H. B., Elhadef, K., Braïek, O. B., Ennouri, K., Mtibaa, A. C., & Mellouli, L. (2020) · Plant Foods for Human Nutrition · doi:10.1007/s11130-020-00863-7 · Cited by 95
González‐Pérez, A., Sáez, M. E., Vizcaya, D., Lind, M., & Rodríguez, L. G. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002146 · Cited by 91
Chen, H.-Y., Kuo, S., Su, P.-F., Wu, J., & Ou, H. (2020) · Diabetes Care · doi:10.2337/dc20-0072 · Cited by 82
Wu, Y., Xiong, T., Tan, X. W., & Chen, L. (2022) · BMC Medicine · doi:10.1186/s12916-022-02675-9 · Cited by 77
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease
McEwan, P. C., Darlington, O. T., Miller, R. L., McMurray, J. J. V., Wheeler, D. C., Heerspink, H. J. L., Briggs, A. H., Bergenheim, K., & Sánchez, J. J. G. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03790322 · Cited by 69
“73 m(2) 20,731 (31) 56,405 (33) 16,184 (34) Dialysis 47,565 (7) 73,896 (35) 58,062 (34) Transplant 28,199 (36) 146,899 (37) 26,989 (38) Events Hospitalization for heart failure 7255 (39) 6576 (40) 4000 (38) Acute decline in kidney function 187 (29) 100 (30) 99 (30) Volume depletion 46 (41) 36 (30) 3193 (38) Major hypo…”
Alzaid, A., de Guevara, P. L., Beillat, M., Martin, V. L., & Atanasov, P. Y. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1782748 · Cited by 82
Khajebishak, Y., Payahoo, L., Alivand, M. R., Hamishehkar, H., Mobasseri, M., Ebrahimzadeh, V., Alipour, M., & Alipour, B. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28561 · Cited by 71
“Diabetes imposes a considerable burden on healthcare (Kähm et al., 2018).”
BackgroundWan, H., Wang, B., Cui, Y., Wang, Y., Zhang, K., Chen, C., Xia, F., Ye, L., Wang, L., Wang, N., et al. (2021) · Chemosphere · doi:10.1016/j.chemosphere.2021.130111 · Cited by 47
DNA methylation age acceleration is associated with risk of diabetes complications
Vetter, V. M., Spieker, J., Sommerer, Y., Buchmann, N., Kalies, C. H., Regitz‐Zagrosek, V., Bertram, L., & Demuth, I. (2023) · Communications Medicine · doi:10.1038/s43856-023-00250-8 · Cited by 48
Lemche, E., Killick, R., Mitchell, J., Caton, P., Choudhary, P., & Howard, J. K. (2024) · Neurobiology of Disease · doi:10.1016/j.nbd.2024.106485 · Cited by 54
Long short-term memory neural network for glucose prediction
Carrillo-Moreno, J., Gandía, C. P., Sendra-Arranz, R., García-Sáez, G., Hernando, M. E., & Gutiérrez, Á. (2020) · Neural Computing and Applications · doi:10.1007/s00521-020-05248-0 · Cited by 45
Wang, Y., Zhang, P., Shao, H., Andes, L. J., & Imperatore, G. (2022) · Diabetes Care · doi:10.2337/dc21-2151 · Cited by 48
Iacobini, C., Vitale, M., Haxhi, J., Pesce, C. M., Pugliese, G., & Menini, S. (2022) · Antioxidants · doi:10.3390/antiox11112183 · Cited by 46
“Most of the harms and costs related to diabetes are due to its long-term microvascular (nephropathy, retinopathy, and neuropathy) and macrovascular (coronary, cerebrovascular, and peripheral artery disease) complications [3].”
BackgroundViggers, R., Jensen, M. H., Laursen, H. V. B., Drewes, A. M., Vestergaard, P., & Olesen, S. S. (2021) · Diabetes Care · doi:10.2337/dc21-0333 · Cited by 47
Zhang, C., Zhang, Q., Zhang, X., Du, S., Zhang, Y. E., Wang, X., Liu, Y., Fang, B., Chen, J., Liu, R., et al. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.11.042 · Cited by 48
Stegbauer, C., Falivena, C., Moreno, A., Hentschel, A., Rosenmöller, M., Heise, T., Szécsényi, J., & Schliess, F. (2020) · BMC Health Services Research · doi:10.1186/s12913-020-05897-w · Cited by 45
Wan, H., Wang, Y., Zhang, K., Chen, Y., Fang, S., Zhang, W., Wang, C., Li, Q., Xia, F., Wang, N., et al. (2019) · Endocrine Practice · doi:10.4158/ep-2019-0015 · Cited by 35
Estimating costs of diabetes complications in people <65 years in the U.S. using panel data
Yang, W., Cintina, I., Hoerger, T. J., Neuwahl, S. J., Shao, H., Laxy, M., & Zhang, P. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107735 · Cited by 36
Self-citationPereira‐Figueiredo, D., Nascimento, A., Cunha-Rodrigues, M. C., Brito, R., & Calaza, K. D. C. (2021) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01077-4 · Cited by 41
Emmert-Fees, K. M. F., Amies‐Cull, B., Wawro, N., Linseisen, J., Staudigel, M., Peters, A., Cobiac, L. J., O’Flaherty, M., Scarborough, P., Kypridemos, C., et al. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004311 · Cited by 46
Self-citationBetts, K. A., Song, J., Faust, E., Yang, K., DU, Y., Kong, S. X., & Singh, R. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88807 · Cited by 39
Li, J., Gu, L., & Guo, Y. (2019) · Journal of Clinical Nursing · doi:10.1111/jocn.14810 · Cited by 33
Hoogendoorn, M., Galekop, M. M. J., & van Baal, P. H. M. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15116 · Cited by 29
Persson, S., Johansen, P., Andersson, E., Lindgren, P., Thielke, D., Thorsted, B. L., JENDLE, J. H., & Carlsson, K. S. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14070 · Cited by 30
Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
Michaeli, D. T., Michaeli, J. C., Boch, T., & Michaeli, T. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07310-y · Cited by 23
Gershater, M. A., & Apelqvist, J. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1773804 · Cited by 24
Jones, A., Bardram, J. E., Bækgaard, P., Cramer-Petersen, C. L., Skinner, T. C., Vrangbæk, K., Starr, L. K., Nørgaard, K., Lind, N., Christensen, M. B., et al. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.10.008 · Cited by 23
Self-citationPochopień, M., Cherney, D. Z. I., Folkerts, K., Lévy, P., Millier, A., Morris, S., Roy-Chaudhury, P., Sullivan, S. D., & Mernagh, P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88808 · Cited by 21
Kähm, K., Stark, R. G., Laxy, M., Schneider, U., & Leidl, R. (2019) · Diabetic Medicine · doi:10.1111/dme.14213 · Cited by 24
Self-citationLaxy, M., Becker, J., Kähm, K., Holle, R., Peters, A., Thorand, B., Schwettmann, L., & Karl, F. M. (2021) · Value in Health · doi:10.1016/j.jval.2020.09.017 · Cited by 22
Self-citationChao, C., Lee, S., Wang, J., Chien, K., & Hung, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01279-6 · Cited by 19
Chen, G., Che, L., Lai, M., Wei, T., Chen, C., Zhu, P., & Ran, J. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01592-7 · Cited by 21
“The increasing rates of diabetes worldwide and the high number of diabetes-related deaths, especially from cardiovascular issues, have led to a focus on identifying factors that can predict mortality in individuals with diabetes [1–3].”
BackgroundPöhlmann, J., Norrbacka, K., Boye, K., Valentine, W. J., & Sapin, H. (2020) · The European Journal of Health Economics · doi:10.1007/s10198-020-01229-1 · Cited by 19
Alendronate Use and Risk of Type 2 Diabetes: A Nationwide Danish Nested Case-Control Study
Viggers, R., Al-Mashhadi, Z. K., Starup‐Linde, J., & Vestergaard, P. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.771426 · Cited by 18
Schuettig, W., & Sundmacher, L. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01428-y · Cited by 25
“Our study was informed by earlier research that identified adjustment for a number of known risk factors for hospitalizations among patients with type 2 diabetes [18, 58, 59].”
MethodInfluentialWan, H., Wang, Y., Chen, Y., Fang, S., Zhang, W., Xia, F., Wang, N., & Lu, Y. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108005 · Cited by 18
Liu, Y., Ning, X., Zhang, L., Long, J., Liang, R., Peng, S., Wang, H., Li, Y., Chen, W., & Xiao, H. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002720 · Cited by 22
Laxy, M., Schöning, V., Kurz, C., Holle, R., Peters, A., Meisinger, C., Rathmann, W., Mühlenbruch, K., & Kähm, K. (2019) · PharmacoEconomics · doi:10.1007/s40273-019-00822-4 · Cited by 18
Self-citationWan, H., Zhu, H., Wang, Y., Zhang, K., Chen, Y., Fang, S., Xia, F., Wang, N., Zhang, W., & Lu, Y. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820937897 · Cited by 17
Chen, C., Chen, Y., Zhai, H., Xia, F., Han, B., Zhang, W., Wang, Y., Wan, H., Wang, N., & Lu, Y. (2020) · Nutrition & Metabolism · doi:10.1186/s12986-020-00493-5 · Cited by 16
Association between Preexisting Sarcopenia and Stroke in Patients with Type 2 Diabetes Mellitus
Chai, K.-C., Chen, W.-M., Chen, M.-H., Shia, B., & Wu, S. (2022) · The journal of nutrition health & aging · doi:10.1007/s12603-022-1846-0 · Cited by 17
“The findings can be used to promote the early detection and reduction of the risk of stroke, thereby preventing the wastage of medical resources and the disability caused by stroke in patients with type 2 diabetes mellitus and increasing their lifespan (41, 42).”
Gabler, M., Geier, S., Mayerhoff, L., & Rathmann, W. (2021) · BMC Public Health · doi:10.1186/s12889-021-10381-z · Cited by 15
He, X., Zhang, Y., Zhou, Y., Dong, C., & Wu, J. H. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00967-y · Cited by 15
Claessen, H., Narres, M., Kvitkina, T., Wilk, A., Friedel, H., Günster, C., Hoffmann, F., Koch, M., Jandeleit-Dahm, K. A. M., & Icks, A. (2021) · Diabetes Care · doi:10.2337/dc20-2477 · Cited by 15
Wang, Y., Zhang, P., Shao, H., Andes, L. J., & Imperatore, G. (2022) · Diabetes Care · doi:10.2337/dc21-2538 · Cited by 16
Dunkel, A., von Storch, K., Hochheim, M., Zank, S., Polidori, M. C., & Woopen, C. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01290-6 · Cited by 18
“In addition to the direct health burden on those who are suffering from the disease, T2DM also places a major financial burden on the health care system, both direct (e.g., treatment costs, secondary diseases) and indirect (e.g., loss of working hours, etc.) [16–19].”
BackgroundWu, J., Wu, Y. Y., Wang, Z., Wu, Y., Wu, T., Wang, M., Wang, X., Wang, S., Wang, J., Yu, H., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18073693 · Cited by 15
“As the largest developing country, China has a growing burden of diabetes [6].”
BackgroundResultInfluentialAlbuminuric diabetic kidney disease predicts foot ulcers in type 2 diabetes
Borderie, G., Foussard, N., Larroumet, A., Blanco, L., Domenge, F., Mohammedi, K., Ducasse, É., Caradu, C., & Rigalleau, V. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108403 · Cited by 11
Kähm, K., Laxy, M., Schneider, U., & Holle, R. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0699-1 · Cited by 12
Self-citationViggers, R., Al-Mashhadi, Z. K., Starup‐Linde, J., & Vestergaard, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.826997 · Cited by 15
“Alendronate 1,289 (40) 1 (reference) 1 (reference) 1 (reference) 1 (reference)”
Monami, M., Ragghianti, B., Nreu, B., Lorenzoni, V., Pozzan, M., Silverii, G. A., Turchetti, G., & Mannucci, E. (2022) · The International Journal of Lower Extremity Wounds · doi:10.1177/15347346221097283 · Cited by 13
Stephan, A., Hanselmann, M., Bajramovic, M., Schoßer, S., & Laxy, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02640-9 · Cited by 14
“Background Diabetes complications have a high economic impact on healthcare systems [1, 2].”
InfluentialSelf-citationArbel, R., Aboalhasan, E., Hammerman, A., & Azuri, J. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa136 · Cited by 12
Häussling, V., Aspera-Werz, R. H., Rinderknecht, H., Springer, F., Arnscheidt, C., Menger, M. M., Histing, T., Nussler, A. K., & Ehnert, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062925 · Cited by 11
“A large proportion of the long-term therapeutic costs for diabetics accounts for the treatment of these bone diseases [8].”
BackgroundACE inhibitor or ARB treatment among patients with diabetes and chronic kidney disease
Fried, L. F., Petruski‐Ivleva, N., Folkerts, K., Schmedt, N., Velentgas, P., & Kovesdy, C. P. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88806 · Cited by 12
Sun, C., van Soest, J., Koster, A., Eussen, S. J. P. M., Schram, M. T., Stehouwer, C. D. A., Dagnelie, P. C., & Dumontier, M. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104194 · Cited by 10
Costs of major complications in people with and without diabetes in Tasmania, Australia
Dinh, N. T. T., de Graaff, B., Campbell, J. A., Jose, M., John, B., Saunder, T., Kitsos, A., Wiggins, N., & Palmer, A. J. (2022) · Australian Health Review · doi:10.1071/ah22180 · Cited by 12
Viggers, R., Starup‐Linde, J., & Vestergaard, P. (2023) · Bone · doi:10.1016/j.bone.2023.116745 · Cited by 12
Kempf, K., Dubois, C., Arnold, M., Amelung, V. E., Leppert, N., Altin, S. V., Vomhof, M., Icks, A., & Martin, S. (2023) · Nutrients · doi:10.3390/nu15183954 · Cited by 13
“, for retinopathy (EUR 700), diabetic foot syndrome (EUR 1300), nephropathy (EUR 3400), myocardial infarction (EUR 8000–8700), stroke (EUR 10,000–11,200), amputation (EUR 14,300), and end-stage renal disease (EUR 22,700) in the quarter of event [2].”
BackgroundJamalnia, S., Javanmardifard, S., Akbari, H., Sadeghi, E., & Bijani, M. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s238247 · Cited by 16
Narres, M., Claessen, H., Kvitkina, T., Koch, M., Rump, L. C., Weinreich, T., & Icks, A. (2019) · Diabetologia · doi:10.1007/s00125-019-05067-6 · Cited by 9
Brinkmann, C. K., Hof, H., Gysan, D.-B., Albus, C., Millentrup, S., Bjarnason‐Wehrens, B., Latsch, J., Herold, G., Wegscheider, K., Heming, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1106334 · Cited by 15
“(22) estimated the costs for diabetic complications in German patients.”
BackgroundHealthcare costs of diabetic foot disease in Italy: estimates for event and state costs
Seghieri, C., Ferré, F., Foresi, E., & Borghini, A. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01462-w · Cited by 10
“A German study using claims data reported that T2D complications significantly affected the total direct health care costs even years after the event, with variations according to demographics and complication type [22].”
BackgroundMethodHatipoğlu, B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.06.006 · Cited by 10
Lui, J. N. M., Lau, E. S. H., Li, A., Zhang, Y., Lim, L.-L., Chun-Kwun, O., Wong, K. T., Yang, A., Wu, H., Ronald, C. W., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111961 · Cited by 8
Erukainure, O. L., Otukile, K. P., Harejane, K. R., Salau, V. F., Aljoundi, A., Chukwuma, C. I., & Matsabisa, M. G. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104842 · Cited by 9
(DOG), D. O. G., (RG), R. G. E. V., & (BVA), B. D. A. D. E. V. (2020) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1097-3440 · Cited by 11
Estimating direct medical costs of type 2 diabetes mellitus in the Philippines: a protocol
Ng, J. Y. S., Clement, I. J., Jimeno, C., Sy, R. A., Mirasol, R. C., Pena, P. D., Panelo, A., Tan, R., Santillan, M., Bayani, D., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2018-025696 · Cited by 8
Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment
Reimer, J., Vogelmann, T., Trümper, D., & Scherbaum, N. (2019) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-019-0247-9 · Cited by 12
Wong, C. K. H., Tong, T., Cheng, G. H. L., Tang, E. H. M., Thokala, P., Tse, E. T. Y., & Lam, C. L. K. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13657 · Cited by 7
(DOG), D. O. G., (RG), R. G. E. V., & (BVA), B. D. A. D. E. V. (2020) · Der Ophthalmologe · doi:10.1007/s00347-019-01015-2 · Cited by 14
Liao, C., Yang, C.-T., Chen, P.-H., Toh, H. S., Kuo, S., Chen, Z., Ou, H., Ko, N., & Wang, J. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487320908085 · Cited by 9
Wal, P., Aziz, N., Prajapati, H., Soni, S., & Wal, A. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998263079231011073803 · Cited by 9
Kim, N. H., Lee, J., Chon, S., Yu, J. M., Jeong, I., Lim, S. K., Kim, W. J., Song, K., Cho, H., Yu, H. M., et al. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.1995 · Cited by 7
“Microvascular complications in T2D pose considerable health and economic burdens comparable with cardiovascular complications [23,24].”
BackgroundLinnemann, C., Savini, L., Rollmann, M. F. R., Histing, T., Nussler, A. K., & Ehnert, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179212 · Cited by 6
“The treatment of bone diseases accounts for a large proportion of the long-term therapeutic costs for diabetics [11], highlighting the need for new therapeutic options.”
BackgroundPersson, S., Nilsson, K., Karlsdotter, K., Skogsberg, J., Gustavsson, S., JENDLE, J. H., & Carlsson, K. S. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14919 · Cited by 5
Sund, R., Peltonen, T. O., Lehtimäki, A.-V., & Martikainen, J. A. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-07895-6 · Cited by 8
The Economic Costs of Diabetes
Rodríguez‐Saldaña, J. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_3 · Cited by 6
Jabbar, R. M., Al‐Jumaili, A. A., Alkhatib, N. S., & Jaafar, A. D. (2025) · International Journal of Pharmacy Practice · doi:10.1093/ijpp/riaf075 · Cited by 5
Fan, M., Stephan, A., Emmert-Fees, K. M. F., Peters, A., & Laxy, M. (2023) · Diabetologia · doi:10.1007/s00125-023-05950-3 · Cited by 8
Self-citationNgari, D. M., Mbisi, A. M., & Njogu, T. W. (2020) · Open Journal of Clinical Diagnostics · doi:10.4236/ojcd.2020.101001 · Cited by 5
“Another research done in Germany revealed that the cost of diabetes management differed between age groups and insurance cover for all that helped cut the costs [25].”
BackgroundGerman Society of Ophthalmology (DOG), & German Retina Society (RG) (2020) · Der Ophthalmologe · doi:10.1007/s00347-020-01244-w · Cited by 6
Huang, Y., Jiang, K., Liu, Y., Mo, W., Zeng, Y., Yang, Y., & Bi, J. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04402-x · Cited by 4
Sarabhai, T., & Kostev, K. (2025) · Journal of Diabetes · doi:10.1111/1753-0407.70099 · Cited by 4
“The increase in the number of people with T2D or with a longer duration of T2D is likely to alter the disease profile and health-care costs, particularly, due to a higher incidence of diabetes-specific complications [6].”
Rucci, P., Avaldi, V. M., Travaglini, C., Ugolini, C., Berti, E., Moro, M. L., & Fantini, M. P. (2019) · PharmacoEconomics - Open · doi:10.1007/s41669-019-0166-8 · Cited by 5
Microcirculation of the Diabetic Foot
Zhang, Y., Mezghani, I., & Veves, A. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_16 · Cited by 3
(2023) · Journal of Wound Management Official journal of the European Wound Management Association · doi:10.35279/jowm2023.24.02.06 · Cited by 3
Meuffels, F. M., Lichtmess, C., Kreutz, T., Held, S., & Brinkmann, C. K. (2025) · Diabetology · doi:10.3390/diabetology6080077 · Cited by 4
Jabbar, R. M., Al‐Jumaili, A. A., & Jaafar, A. D. (2026) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-026-00717-0 · Cited by 2
Impact of Diabetes Complications
Smokovski, I. (2020) · Springer eBooks · doi:10.1007/978-3-030-51469-3_3 · Cited by 2
Lauwers, P., Hendriks, J. M. H., Wouters, K., Vanoverloop, J., Avalosse, H., Dirinck, E. L., Nobels, F. R. E., Dumont, I., Felix, P., & Matricali, G. A. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111072 · Cited by 2
Diabetes mellitus: Kosten von Komplikationen erstmals detailliert berechnet
Kähm, K., Holle, R., & Laxy, M. (2018) · Deutsches Ärzteblatt · doi:10.3238/persdia.2018.04.27.03 · Cited by 2
Self-citationZufry, H., Sucipto, K. W., Ekadamayanti, A. S., Firdausa, S., & Debbyousha, M. (2025) · Seminars in Dialysis · doi:10.1111/sdi.70007 · Cited by 1
The Financial Burden of Prediabetes and Diabetes in Trauma Care Under the G-DRG System
Tercan, E., Tombaz, M., Huber, P., Rollmann, M. F. R., Nussler, A. K., & Ehnert, S. (2026) · Zeitschrift für Orthopädie und Unfallchirurgie · doi:10.1055/a-2861-4883 · Cited by 1
Metadata
- Authors
- Kähm, K., Laxy, M., Schneider, U., Rogowski, W. H., Lhachimi, S. K., & Holle, R.
- Affiliations
- Helmholtz Munich (DE)
- Techniker Krankenkasse (Germany) (DE)
- University of Bremen (DE)
- Corresponding author
- Kähm, Katharina
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2018-01-18
- Volume
- 41
- Issue
- 5
- Pages
- 971-978
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2789481148
- Cited by
- 141
- References
- 33
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 12 · 2023: 19 · 2022: 24 · 2021: 20 · 2020: 29 · 2019: 13 · 2018: 9
- FWCI
- 27.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
- Keywords
- type 2 diabetes, diabetes complications, health care costs, economic burden of disease, diabetic foot, amputation, diabetic retinopathy, blindness, diabetic nephropathy, end-stage renal disease, stroke, myocardial infarction, ischemic heart disease, chronic heart failure, angina pectoris, sex differences, age differences, statutory health insurance, Germany
- MeSH terms
- Aged, Ambulatory Care, Amputation, Surgical, Diabetes Mellitus, Type 2, Female, Germany, Heart Failure, Humans, Male, Middle Aged, Myocardial Infarction, Health Care Costs, Diabetic Foot, Stroke, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.